Axogen, Inc. Q4 FY2024 earnings call

Key Points

• Michael Dale noted 2024 was a solid year with key accomplishments and introduced new strategic priorities, to be detailed at March 4 Investor Day.
• Jens Kemp outlined strategic priorities including: prioritizing elective/planned procedures, advancing extremities business (driving Avance Nerve Graft as standard of care, optimizing patient journey, expanding lower extremities market, driving commercial excellence), leading breast neurotization (increasing commercial infrastructure, expanding surgeon education, accelerating patient awareness), growing oral/maxillofacial/head and neck business (expanding surgeon education, increasing market development support, leveraging societal support), developing prostate nerve repair, investing in innovation, and driving operational efficiencies.
• Nir Naor discussed fourth quarter financial results: revenue $49.4M (+15.1% y/y), gross profit $37.6M, gross margin 76.1% (up from 74.6% y/y), operating expenses, net income, adjusted net income, and EBITDA. Also mentioned cash balance and full year 2025 guidance.

Full year 2024 revenue was $187.3 million, a 17.8% increase compared to 2023. Fourth quarter 2024 revenue was $49.4 million, up 15.1% compared to the prior year. Broad-based growth was seen across all markets served, including extremities, oral, maxillofacial, head and neck, and breast. Each market's positive performance was driven by improved commercial execution of the nerve repair algorithm and development of high potential accounts. EBITDA was positively impacted by improved sales productivity and resource allocation.

Guidance

• Full year 2025 revenue growth expected in the range of 15% to 17% versus the prior year.
• Full-year 2025 gross margin expected in the range of 73% to 75%, including approximately $2 million of one-time costs related to BLA approval.
• Expect to be net cash flow positive for the entire year 2025, with Q1 expected to be a net cash outflow due to yearly bonus payment and national sales meeting, followed by positive cash flow for the remainder of the year.

Risks

• Uncertainties related to the timing of BLA approval for Avance Nerve Graft.
• Challenges in market adoption and commercial execution, particularly in certain segments like extremities with complex patient journeys and payer coverage policies.
• Potential capacity constraints if not properly planned for in the future.
• Regulatory uncertainties and the need for continued data generation and clinical evidence for new markets and applications.

Q: Chris Pasquale asked about the $5 billion TAM and how it differs from previous estimates, and whether the company can balance investment with profitability.

A: Michael Dale stated the TAM was evaluated through thorough analysis of incidence, presentation, and addressability, and the plan is practical and doable. Nir Naor added it's a balanced growth with optimization of resource allocation.

Q: Michael Sarcone inquired about the 15%-20% CAGR assumption and sales cadence for 2025.

A: Michael Dale mentioned the plan is executable with tied math based on past performance and investments. Nir Naor noted key assumptions include existing momentum and staggered investment impact, with seasonality expected in top-line.

Q: Caitlin Cronin asked about long-term margins and BLA application with new administration.

A: Michael Dale said 2025 focus is on BLA process with incremental margin improvements expected longer term. He stated no delays seen in FDA review.

Q: Mike Kratky asked about sales and marketing expansion and identifying high potential accounts.

A: Michael Dale mentioned doubling breast sales force and using an algorithm to identify high potential accounts (Level 1 trauma centers, microsurgically trained surgeons, high nerve repair cases).

Q: Jayson Bedford inquired about prostate nerve repair data and gross margin trends.

A: Michael Dale said prostate fits within BLA but more data is needed. Nir Naor explained gross margin impacted by Avance product mix and efficiency improvements needed.

Q: Ross Osborn asked about prostate data needs and breast data comfort.

A: Michael Dale stated breast has strong benefit-risk but needs more data. Prostate requires additional data for full launch.

Q: Dave Turkaly asked about capacity and share count.

A: Michael Dale said capacity is comfortable during planning period. Nir Naor noted share count reported is to be used and no near-term raise expected